Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 513

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 513
---
 non-cancellable commitments, minimum purchase commitments, and binding annual forecasts. As of December 31, 2023, there were non-cancellable purchase
commitments under the Fresenius Agreement related to the purchase of inventory for $4.9 million to be paid in 2024.

Mirati Collaboration

In October 2022, the Company entered into a collaboration and supply agreement with Mirati Therapeutics, Inc. (“Mirati”) to evaluate the
combination of Mirati’s adagrasib, a KRAS selective inhibitor, and FYARRO in KRAS mutant
non-small cell lung cancer (NSCLC) and other solid tumors. Under the terms of the agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study and the Company will supply study drug
and jointly share the cost of the study.

The primary objective of this multi-center, single-arm, open-label Phase
1/2 trial is to determine the optimal dose and recommended Phase 2 dose for the combination of adagrasib and FYARRO in patients with KRAS

F-30

mutant solid tumors. In addition, the study will investigate the safety, tolerability and efficacy of adagrasib and FYARRO in combination in patients both with and without prior exposure to a
KRAS inhibitor. The trial will build on preclinical data showing enhanced anti-tumor efficacy with the combination of adagrasib and FYARRO relative to either agent alone.

For the year ended December 31, 2023, the Company incurred $0.9 million in expenses related to the Mirati collaboration. For the year ended
December 31, 2022, no expense was incurred related to the Mirati collaboration.

14. Employee Retirement Plan

The Company maintains a 401(k) plan (the “401k Plan”) created in 2015 for the benefit of its employees. All employees who have attained the age of 21
are eligible to participate in the 401k Plan as of the first entry date, as defined by the 401k Plan document, following the employment date. Each employee can contribute a percentage of compensation up to a maximum of the statutory limits per year.
Company contributions are discretionary. Contributions of $0.7 million and $0.5 million were made during the years ended December 31, 2023 and 2022.

F-31

PART I – FINANCIAL INFORMATION Item 1. Financial Statements. AADI BIOSCIENCE